Inflammed skin harbours Th9 cells

Acta Dermato-Venereologica

Volumn 93, Issue 2, 2013, Pages 183-185

  Cortelazzi, Chiara ^a   Campanini, Nicoletta ^a   Ricci, Roberto ^a   De Panfilis, Giuseppe ^a  

^a Department of Dermatology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CD4 ANTIGEN; INTERLEUKIN 9; TRANSCRIPTION FACTOR PU 1;

ADULT; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; HISTIOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS VULGARIS; SKIN ALLERGY; SKIN INFILTRATE;

BIOLOGICAL MARKERS; BIOPSY; DERMATITIS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-9; PROTO-ONCOGENE PROTEINS; SKIN; T-LYMPHOCYTES, HELPER-INDUCER; TRANS-ACTIVATORS;

EID: 84873666743     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1408     Document Type: Letter

References (15)

1. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, A Westendorf, Buer J, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008; 9: 1341-1346.
2. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008; 9: 1347-1355.
3. Tan C, Aziz MK, Lovaas JD, Vistica BP, Shi G, Wawrousek EF, et al. Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site. J Immunol 2010; 185: 6795-6801.
4. Chang HC, Sehra S, Goswami R, Yao W, Yu Q, Stritesky GL, et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol 2010; 11: 527-534.
5. Perumal NB, Kaplan MH. Regulating Il9 transcription in T helper cells. Trends Immunol 2011; 32: 146-150.
6. Muirhead D, Stone MS, Syrbu SI. The utility of PU.1 as an immunohistochemical marker for histiocytic and dendritic lesions of the skin. Am J Dermatopathol 2009; 31: 432-435.
7. De Panfilis G, Campanini N, Santini M, Mori G, Tognetti E, Maestri R, et al. Phase-and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma. J Invest Dermatol 2008; 128: 676-684.
8. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010; 10: 683-687.
9. Soroosh P, Doherty TA. Th9 and allergic disease. Immunology 2009; 127: 450-458.
10. Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol 2000; 105: 108-115.
11. Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med 2011; 11: 14-23.
12. De Panfilis G, Manara GC, Ferrari C, Torresani C, Zucchi A, Devoto RM. Further characterization of the "incipient lesion of chronic stationary type psoriasis vulgaris in exacerbation". The CD4-positive lymphocytes are the prominent cell population infiltrating the dermis. Acta Derm Venereol Suppl 1989; 146: 26-30.
13. Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA 2009; 106: 12885-12890.
14. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009; 206: 1653-1660.
15. Cavani A, De Luca A. Allergic contact dermatitis: novel mechanisms and therapeutic perspectives. Current Drug Metabolism 2010; 11: 228-233.